Table of Contents PART 01: Executive summary PART 02: Scope of the report PART 03: Research Methodology PART 04: Introduction • Key market highlights PART 05: An overview of muscle spasticity and spasms PART 06: Pipeline landscape PART 07: Market landscape • Market overview • Five forces analysis PART 08: Market segmentation by product category • Skeletal muscle relaxant drugs • Facial muscle relaxant drugs PART 09: Geographical segmentation • Muscle relaxant drugs market in Americas • Muscle relaxant drugs market in EMEA • Muscle relaxant drugs market in APAC PART 10: Decision framework PART 11: Drivers and challenges • Market drivers • Impact of drivers on key customer segments • Market challenges • Impact of challenges on key customer segments PART 12: Market trends • Anti-aging treatments driving adoption of facial relaxants • Advanced drug delivery technologies fuels adoption of muscle relaxants • Growing use of muscle relaxants in new indications and applications PART 13: Vendor landscape • Competitive scenario PART 14: Key vendor analysis • Pfizer • Allergan • Ipsen Group • Teva Pharmaceuticals • Novartis • Other prominent vendors PART 15: Appendix • List of abbreviations List of Exhibits Exhibit 01: Key muscle relaxants Exhibit 02: Pipeline landscape Exhibit 03: Global muscle relaxant drugs market snapshot Exhibit 04: Global muscle relaxant drugs market 2016-2021 ($ millions) Exhibit 05: Opportunity analysis in global muscle relaxant drugs market Exhibit 06: Five forces analysis Exhibit 07: Global muscle relaxant drugs market by product category 2016 Exhibit 08: Global skeletal muscle relaxant drugs market 2016-2021 ($ millions) Exhibit 09: Global facial muscle relaxant drugs market 2016-2021 ($ millions) Exhibit 10: Global muscle relaxant drugs market by geography 2016 and 2021 Exhibit 11: Global muscle relaxant drugs market revenue by geography 2016-2021 ($ millions) Exhibit 12: Market scenario in Americas Exhibit 13: Muscle relaxant drugs market in Americas 2016-2021 ($ millions) Exhibit 14: Market scenario in EMEA Exhibit 15: Muscle relaxant drugs market in EMEA 2016-2021 ($ millions) Exhibit 16: Market scenario in APAC Exhibit 17: Muscle relaxant drugs market in APAC 2016-2021 ($ millions) Exhibit 18: Key approvals for new indications Exhibit 19: Key factors driving the market growth Exhibit 20: Impact of drivers Exhibit 21: Impact of challenges Exhibit 22: Competitive structure analysis of global muscle relaxant drugs market 2016 Exhibit 23: Competitive analysis of global muscle relaxant drugs market Exhibit 24: Strategic success factors of companies in global muscle relaxant drugs market Exhibit 25: Pfizer: Strength assessment Exhibit 26: Pfizer: Strategy assessment Exhibit 27: Pfizer: Opportunity assessment Exhibit 28: Allergan: Key highlights Exhibit 29: Allergan: Strength assessment Exhibit 30: Allergan: Strategy assessment Exhibit 31: Allergan: Opportunity assessment Exhibit 32: Ipsen Group: Key highlights Exhibit 33: Ipsen Group: Strength assessment Exhibit 34: Ipsen Group: Strategy assessment Exhibit 35: Ipsen Group: Opportunity assessment Exhibit 36: Teva Pharmaceuticals: Strength assessment Exhibit 37: Teva Pharmaceuticals: Strategy assessment Exhibit 38: Teva Pharmaceuticals: Opportunity assessment Exhibit 39: Novartis: Strength assessment Exhibit 40: Novartis: Strategy assessment Exhibit 41: Novartis: Opportunity assessment

Pfizer, Ipsen Group, Allergan, Novartis, Teva Pharmaceuticals, Acorda Therapeutics, Aldeyra Therapeutics, Canbex Therapeutics, Daewoong, Emcure Pharmaceuticals, Endo International, Fresenius Kabi, Galderma, INSYS Therapeutics, Johnson & Johnson, Lannett Company, Merz Pharma, Mylan, Par Pharmaceutical, PhytoTech Therapeutics, Revance Therapeutics, Sun Pharmaceutical Industries, and Takeda Pharmaceutical.